Drug intelligence / Profile preview

mRNA-1273.712

Development stage: Phase 4
Lead developer: Moderna
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

mRNA-1273.712 appears to be a COVID-19 vaccine candidate developed by Moderna. It is likely a variant-specific or updated formulation of Moderna's original COVID-19 vaccine (mRNA-1273). Like the original mRNA-1273, it would contain synthetic nucleoside-modified messenger RNA (mRNA) encapsulated in lipid nanoparticles (LNPs) that encodes for a prefusion stabilized spike (S) protein of SARS-CoV-2. The vaccine works by instructing human cells to produce the SARS-CoV-2 spike protein, which then triggers an immune response against the virus.

Targets

SARS-CoV-2 spike non-RBD epitopesRBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on mRNA-1273.712.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mRNA-1273.712.

Explore the full profile